MarketCap
Facebook
X
Telegram
MTBC Revenue | MTBC
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue MTBC
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 120 M | 111 M | 117 M | 139 M | 140 M | 105 M | 64.4 M | 50.5 M | 31.8 M | 24.5 M | 23.1 M | 18.3 M | 10.5 M | 10 M | 10.1 M |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 140 M | 10 M | 65 M |
Quarterly Revenue MTBC
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 31.9 M | 31.3 M | 31.1 M | 27.4 M | 27.6 M | - | 28.5 M | 28.1 M | 26 M | - | 29.3 M | 29.4 M | 30 M | - | 33.7 M | 37.2 M | 35.3 M | - | 38.3 M | 34.1 M | 29.8 M | - | 31.6 M | 19.6 M | 21.9 M | - | 16.9 M | 16.7 M | 15.1 M | - | 17 M | 8.68 M | 8.31 M | - | 7.51 M | 7.78 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 38.3 M | 7.51 M | 25 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Health information services industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Premier
PINC
|
263 M | - | - | $ 2.33 B |  USA |
 |
Streamline Health Solutions
STRM
|
17.9 M | - | - | $ 21.4 M | USA |
 |
SCWorx Corp.
WORX
|
2.88 M | $ 7.25 | 31.34 % | $ 52.7 M | USA |
 |
American Well Corporation
AMWL
|
249 M | $ 13.44 | -0.92 % | $ 216 M | USA |
 |
Covetrus
CVET
|
4.58 B | - | - | $ 2.94 B | USA |
 |
NextGen Healthcare
NXGN
|
653 M | - | - | $ 1.6 B | USA |
 |
1Life Healthcare
ONEM
|
1.05 B | - | - | $ 3.37 B | USA |
 |
R1 RCM
RCM
|
1.47 B | - | - | $ 3.81 B | USA |
 |
Signify Health
SGFY
|
184 M | - | -0.02 % | $ 7.21 B | USA |
 |
Tabula Rasa HealthCare
TRHC
|
300 M | - | - | $ 255 M | USA |
 |
Change Healthcare
CHNG
|
3.48 B | - | - | $ 9.03 B | USA |
 |
Cerner Corporation
CERN
|
5.76 B | - | - | $ 27.9 B | USA |
 |
iCAD
ICAD
|
19.6 M | - | - | $ 102 M | USA |
 |
Accolade
ACCD
|
414 M | - | 0.29 % | $ 206 M | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
594 M | - | -10.39 % | $ 886 M | USA |
 |
NantHealth
NH
|
67 M | - | -46.64 % | $ 10.4 M | USA |
 |
Health Catalyst
HCAT
|
311 M | $ 1.65 | -2.66 % | $ 115 M | USA |
 |
HealthStream
HSTM
|
304 M | $ 34.57 | -1.65 % | $ 1.04 B | USA |
 |
Omnicell
OMCL
|
1.18 B | $ 37.37 | -1.01 % | $ 1.72 B | USA |
 |
OptimizeRx Corporation
OPRX
|
109 M | $ 8.98 | -1.91 % | $ 167 M | USA |
 |
Phreesia
PHR
|
481 M | $ 12.63 | -0.51 % | $ 754 M | USA |
 |
GoodRx Holdings
GDRX
|
797 M | $ 3.52 | -0.56 % | $ 1.25 B | USA |
 |
HealthEquity
HQY
|
1.31 B | $ 103.34 | -0.61 % | $ 8.9 B | USA |
 |
Schrödinger
SDGR
|
256 M | $ 24.58 | 3.28 % | $ 1.81 B | USA |
 |
Teladoc Health
TDOC
|
2.53 B | $ 6.18 | -2.6 % | $ 1.09 B | USA |
 |
Veeva Systems
VEEV
|
3.2 B | $ 318.06 | -1.51 % | $ 52.1 B | USA |
 |
Zhongchao
ZCMD
|
11.4 M | $ 1.2 | -6.98 % | $ 4.1 M |  China |
 |
So-Young International
SY
|
1.52 B | $ 2.13 | 0.71 % | $ 166 M | China |
 |
Castlight Health, Inc.
CSLT
|
147 M | - | -7.28 % | $ 227 M | USA |
 |
HMS Holdings Corp.
HMSY
|
673 M | - | - | $ 3.29 B | USA |
 |
Inovalon Holdings, Inc.
INOV
|
668 M | - | - | $ 6.37 B | USA |
 |
Evolent Health
EVH
|
469 M | $ 4.39 | -6.98 % | $ 501 M | USA |
 |
Progyny
PGNY
|
318 M | $ 28.34 | -2.17 % | $ 2.42 B | USA |
 |
10x Genomics
TXG
|
643 M | $ 73.51 | 2.74 % | $ 9.17 B | USA |
 |
Computer Programs and Systems
CPSI
|
347 M | - | 4.4 % | $ 133 M | USA |
 |
Akerna Corp.
KERN
|
185 M | - | - | $ 161 M | USA |